Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Pancreatic survival improved with trial chemotherapy regimen after surgery

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 662
Rating:

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Dr Conroy speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about administering mFOLFIRINOX to patients with surgically resected pancreatic cancer

He describes how, compared to those receiving the current standard of care, trial participants had improved median DFS and OS.

For more on these findings, watch his presentation of the results at a press session, or read news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation